Krystal Biotech is trading at $333.34, up 7.01%, in pre-market on October 26, 2026; no clear new company-specific catalyst was identified. - The latest company release schedules third-quarter results for November 2. - The KB113 clinical update was announced October 15, not overnight. - Supplied market indicators were mixed and showed only modest moves, offering no clear explanation for the rise; pre-market volume information was unavailable.